|Bid||25.39 x 800|
|Ask||25.40 x 800|
|Day's Range||24.41 - 25.60|
|52 Week Range||7.76 - 28.79|
|Beta (3Y Monthly)||2.28|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 7, 2018 - May 11, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||30.00|
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Voyager Therapeutics...
Hedge Funds and other institutional investors have just completed filing their 13Fs with the Securities and Exchange Commission, revealing their equity portfolios as of the end of March. At Insider Monkey, we follow nearly 750 active hedge funds and notable investors and by analyzing their 13F filings, we can determine the stocks that they are […]
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 17) ArQule, Inc. (NASDAQ: ARQL )( reported positive results ...
Voyager Therapeutics, Inc. (VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced a restructuring of its gene therapy relationship with Sanofi Genzyme. The ex-U.S. rights to VY-FXN01 are, in turn, transferred from Voyager to Neurocrine Biosciences under the terms of the collaboration agreement between Voyager and Neurocrine Biosciences announced in January 2019.
CAMBRIDGE, Mass., June 11, 2019 -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe.
Thanks to advances in technology and gene sequencing, gene therapy has gone from science fiction to science fact. By either adding new genes to fight faulty ones, replacing/editing missing/broken prices or actually "turning off" the genes causing problems, gene therapy has the potential to change the game when it comes to biotech stocks and healthcare.That's great news, as there are more than 10,000 different disorders and diseases caused by faulty genes.With the FDA launching several fast-track programs for gene therapies last summer, the biotech stocks that specialize in these cutting-edge treatments could see their drugs hit the market that much faster. And yet, the recent market sell-off has caused many of the biotech stocks looking at gene therapy to crater. Given their game-changing potential, these days many stocks in the sector could be considered bargains.InvestorPlace - Stock Market News, Stock Advice & Trading TipsSome more than others. * 7 Stocks to Sell Amid an Escalating Trade War Which gene-therapy biotech stocks have great potential to soar over the long haul? Here are three stocks to buy that could do just that. Gene Therapy Stocks to Buy: CRISPR Therapeutics (CRSP)Source: Shutterstock Clustered Regularly Interspaced Short Palindromic Repeats is a mouthful to say, which is why scientists have shortened it to just CRISPR. CRISPR is the latest method of gene editing and offers cheaper, simpler and faster slicing and dicing of genes. As its name implies, CRISPR Therapeutics (NASDAQ:CRSP) uses the technique.CRSP stock is targeting blood diseases such as beta-thalassemia and sickle cell disease- which are caused by the same mutation. The beauty of this is that the biotech has been able to move ahead at the same time for both indications. Partnering with biotech giant Vertex Pharmaceuticals (NASDAQ:VRTX), CRSP's lead candidate -- CTX001 -- started phase 1 clinical trials this past February. This trial marks the first time in history that a human trial for a CRISPR-based product has been conducted.Naturally, a lot is riding on the trial- especially with the drug winning FDA fast track status. If results are even somewhat positive, CRSP stock could surge higher.But CTX001 isn't the only drug in CRSP's arsenal. The firm is working one several oncology products as well as new gene editing therapies for muscular dystrophy and cystic fibrosis. These drugs could provide plenty of upside as well down the road.In the end, if you're looking for biotech stocks to buy that are looking at gene therapy, CRISPR Therapeutics could be a major star. uniQure NV (QURE)Source: Shutterstock When it comes to biotech stocks, uniQure (NASDAQ:QURE) is gene therapy royalty. That's because the firm actually created and launched the very first successful gene therapy back in 2012. However, due to the cost of the drug, it was never prescribed. But QURE has turned that successful approval into a platform for further successful development.This includes the biotech stock's latest work for hemophilia. QURE has seen great success with its gene therapy program for the blood disorder. After seeing amazing initial results, QURE has moved its top hemophilia medication -- AMT-061 -- into phase I/IIb trials. This news sent the clinical stage biotech stock up more than 34%. Given its past history of navigating the gene therapy waters to approval, QURE could have another hit on its hand.Elsewhere, the firm has started trials for the first gene therapy targeting Huntington's disease and has gene therapies for congestive heart failure in pipelines. All of these are much more "popular" issues and should help QURE actually see prescription growth if successful. * 7 Stocks to Buy for June Like most clinical-stage biotech stocks, QURE is a gamble. But it's a more calculated risk than most given its history and how great its previous results were. Voyager Therapeutics (VYGR)Source: Shutterstock When it comes to clinical stage biotech stocks, it pays to look at partnerships. For gene therapy play Voyager Therapeutics (NASDAQ:VYGR), partnerships include biotech giant AbbVie (NYSE:ABBV), neurological specialist Neurocrine Biosciences (NASDAQ:NBIX) and major pharma stock Sanofi (NASDAQ:SNY). All three of those major players have provided VYGR with some major cash infusions to develop its technology and gene therapy applications. Most clinical biotech stocks would kill to have more than $360 million in cash on their balance sheets.That cash will provide it plenty of working capital to develop its lucrative gene therapy portfolio.And lucrative it will be. VYGR is targeting Parkinson's disease, Amyotrophic Lateral Sclerosis (ALS), Huntington's disease and Alzheimer's disease. These are some of the hardest diseases to crack and winners here will be massive achievements. It seems that Voyager may just get there.So far, results for the firm's tech have been pretty positive, which could explain all the major partnerships. Back in March, Voyager announced that its initial trial for VY-AADC demonstrated improvement in clinical measures for Parkinson's Disease. This success prompted VYGR to start phase II trials -- with results coming in mid-2020. Meanwhile, the firm is moving forward with initial trials with its other partners and developing a robust pipeline. With ample cash, VYGR has plenty of time to get these therapies through testing. Fast track designation from the FDA doesn't hurt either.All in all, VYGR represents a great gene therapy play thanks to its leading partners. Clearly, they see the good in the biotech stocksAt the time of writing, Aaron Levitt was long CRSP and VYGR stock More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 7 Stocks to Sell Amid an Escalating Trade War * 5 REITs to Buy While They're Dirt Cheap * The Only 3 Marijuana Stocks You Need to Own Compare Brokers The post 3 Top Gene Therapy Stocks That Could Soar appeared first on InvestorPlace.
Voyager Therapeutics, Inc. (VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced the retirement of Dinah Sah, Ph.D. as Voyager’s chief scientific officer, and the appointment by Voyager of Omar Khwaja, M.D., Ph.D., currently Voyager’s chief medical officer, to the expanded role of chief medical officer and head of research and development. Dr. Sah has agreed to serve as a consultant to Voyager and become a member of its scientific advisory board.
Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of -2.53% and 73.06%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
The Cambridge, Massachusetts-based company said it had a loss of 81 cents per share. The results missed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research ...
Voyager Therapeutics, Inc. (VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today reported its first quarter 2019 financial results, program progress and corporate updates. “The first quarter was an eventful period for Voyager as we announced new collaborations, provided updates to our pipeline programs, and advanced our discovery efforts focused on novel gene therapy capsids that have the potential to cross the blood-brain barrier and target specific cells within the brain after a single, systemic administration,” said Andre Turenne, president and chief executive officer of Voyager.
Neurocrine Biosciences, Inc. (NBIX) and Voyager Therapeutics, Inc. (VYGR) today announced Phase I trial results for VY-AADC from eight patients with Parkinson’s disease who participated in the open-label trial to evaluate the safety and efficacy of VY-AADC and to further assess the posterior (i.e., from the back of the head) surgical delivery approach. Treatment with VY-AADC improved good ON time (ON time without troublesome dyskinesia) by 1.7 hours from baseline and reduced OFF time by 2.2 hours at 12 months from baseline in patients with Parkinson’s disease.
Voyager Therapeutics (VYGR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! The most recent earnings announcement Voyager Therapeutics, Inc.'s (NASDAQ:VYGR) released in December...
Voyager Therapeutics, Inc. (VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced multiple data presentations at the American Society of Gene and Cell Therapy (ASGCT) taking place April 29-May 2, 2019, in Washington, D.C. New preclinical data at this year’s ASGCT relate to Voyager’s vectorized antibody program directed against tau for the potential treatment of Alzheimer’s disease, its new TRACER™ system to discover adeno-associated virus (AAV) capsids with blood-brain barrier crossing and cell-specific transduction properties, as well as VY-SOD102 targeting a monogenic form of Amyotrophic Lateral Sclerosis (ALS) called SOD1. “One of the major limitations of biologic therapies for the treatment of severe neurodegenerative diseases is the ability of those therapies to cross the blood-brain barrier,” said Dinah Sah, Ph.D., chief scientific officer of Voyager.
CAMBRIDGE, Mass., April 15, 2019 -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe.
Voyager Therapeutics, Inc. (VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, granted restricted stock units and a non-qualified stock option to Robert Hesslein as inducements material to his entering an employment agreement with Voyager to serve as its general counsel. The inducement awards were approved by the Compensation Committee of Voyager’s Board of Directors in accordance with Nasdaq Stock Market Listing Rule 5635(c)(4) and became effective upon the commencement of Mr. Hesslein’s employment on April 1, 2019. Mr. Hesslein received a restricted stock unit award for 28,125 shares of Voyager common stock and a non-qualified stock option to purchase 168,750 shares of Voyager common stock.
CAMBRIDGE, Mass., April 02, 2019 -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe.
Neurocrine Biosciences, Inc. (NBIX) and Voyager Therapeutics, Inc. (VYGR) today announced the publication of interim results from the Phase 1b trial of VY-AADC, an investigational gene therapy treatment for Parkinson’s disease, in the peer-reviewed journal, Annals of Neurology. The publication titled “Magnetic Resonance Imaging-Guided Phase 1 Trial of Putaminal AADC Gene Therapy for Parkinson's Disease,” can be accessed online.
MRI Interventions, Inc. (MRIC) a platform neurosurgery company developing products designed to deliver navigation, ablation, deep brain stimulation, aspiration, biopsy and gene therapy today announced a collaboration with Voyager Therapeutics, Inc. (VYGR) to design, manufacture and supply the Variable Trajectory Array Guide, or V-TAG, neurosurgical device for Voyager. Under the collaboration, Voyager transferred its existing 510(k) clearance for the V-TAG device to MRI Interventions who will manufacture and supply the device as a choice for neurosurgeons, along with MRI’s Clearpoint® system, for use in Voyager’s RESTORE-1 Phase 2 trial of its VY-AADC gene therapy program for Parkinson’s disease. “We continue to evolve and expand our relationship with Voyager with the common goal of delivering gene therapy to specific regions of the brain with accuracy to give our patients the best possible chance at success,” commented Joe Burnett, President and CEO at MRI Interventions.
HENDERSON, NV / ACCESSWIRE / March 8, 2019 / The past few weeks have been busy with big bio taking over smaller biotechs developing novel therapies. Roche (RHHBY) said it would spend $4.8 billion in a ...
NEW YORK, March 06, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.